These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 3924853)

  • 1. Spontaneous immune rejection of intraocular tumors in mice.
    Niederkorn JY; Meunier PC
    Invest Ophthalmol Vis Sci; 1985 Jun; 26(6):877-84. PubMed ID: 3924853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Destructive and nondestructive patterns of immune rejection of syngeneic intraocular tumors.
    Knisely TL; Luckenbach MW; Fischer BJ; Niederkorn JY
    J Immunol; 1987 Jun; 138(12):4515-23. PubMed ID: 3108394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune rejection of metastases arising from intraocular tumors in mice.
    Niederkorn JY; Knisely TL; Mayhew E
    Invest Ophthalmol Vis Sci; 1986 Sep; 27(9):1355-61. PubMed ID: 3091527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histopathologic analysis of intraocular allogeneic tumors in mice.
    Luckenbach MW; Streilein JW; Niederkorn JY
    Invest Ophthalmol Vis Sci; 1985 Oct; 26(10):1368-76. PubMed ID: 3930419
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efferent blockade of delayed-type hypersensitivity responses in the anterior chamber of the eye.
    Niederkorn JY; Benson JL; Mayhew E
    Reg Immunol; 1990-1991; 3(6):349-54. PubMed ID: 2132760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intracamerally induced concomitant immunity: mice harboring progressively growing intraocular tumors are immune to spontaneous metastases and secondary tumor challenge.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Nov; 131(5):2587-94. PubMed ID: 6415174
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Promotion of syngeneic intraocular tumor growth in mice by anterior chamber-associated immune deviation.
    Niederkorn JY; Streilein JW; Kripke ML
    J Natl Cancer Inst; 1983 Jul; 71(1):193-9. PubMed ID: 6575203
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adoptive transfer of immunity to intraocular tumors in mice.
    Niederkorn JY; Streilein JW
    Invest Ophthalmol Vis Sci; 1984 Mar; 25(3):336-42. PubMed ID: 6421767
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space.
    Wenkel H; Chen PW; Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1999 Dec; 40(13):3202-8. PubMed ID: 10586943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alloantigens placed into the anterior chamber of the eye induce specific suppression of delayed-type hypersensitivity but normal cytotoxic T lymphocyte and helper T lymphocyte responses.
    Niederkorn JY; Streilein JW
    J Immunol; 1983 Dec; 131(6):2670-4. PubMed ID: 6196396
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The immunopathology of intraocular tumour rejection.
    Niederkorn JY
    Eye (Lond); 1991; 5 ( Pt 2)():186-92. PubMed ID: 2070879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Termination of systemic immunity in the presence of intraocular tumors: influence of ocular immune privilege on tumor vaccines.
    Chen PW; Ksander BR
    Curr Eye Res; 2006 Jan; 31(1):43-55. PubMed ID: 16421019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deviant immune responses to allogeneic tumors injected intracamerally and subcutaneously in mice.
    Niederkorn J; Streilein JW; Shadduck JA
    Invest Ophthalmol Vis Sci; 1981 Mar; 20(3):355-63. PubMed ID: 6782034
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterization of the suppressor cell(s) responsible for anterior chamber-associated immune deviation (ACAID) induced in BALB/c mice by P815 cells.
    Streilein JW; Niederkorn JY
    J Immunol; 1985 Mar; 134(3):1381-7. PubMed ID: 3155766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor cell surface expression of granulocyte-macrophage colony-stimulating factor elicits antitumor immunity and protects from tumor challenge in the P815 mouse mastocytoma tumor model.
    Soo Hoo W; Lundeen KA; Kohrumel JR; Pham NL; Brostoff SW; Bartholomew RM; Carlo DJ
    J Immunol; 1999 Jun; 162(12):7343-9. PubMed ID: 10358185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of cytotoxic T cell responses to intracameral allogeneic tumors.
    Ksander BR; Streilein JW
    Invest Ophthalmol Vis Sci; 1989 Feb; 30(2):323-9. PubMed ID: 2492486
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Requirement of CD80+ costimulation for rejection of ocular tumors and termination of immune privilege.
    Chen PW; Uno T; Ksander BR
    Exp Eye Res; 2006 Sep; 83(3):574-83. PubMed ID: 16643898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infiltration and accumulation of precursor cytotoxic T-cells increase with time in progressively growing ocular tumors.
    Ksander BR; Bando Y; Acevedo J; Streilein JW
    Cancer Res; 1991 Jun; 51(12):3153-8. PubMed ID: 1904003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ocular immune privilege is circumvented by CD4+ T cells, leading to the rejection of intraocular tumors in an IFN-{gamma}-dependent manner.
    Dace DS; Chen PW; Alizadeh H; Niederkorn JY
    J Leukoc Biol; 2007 Feb; 81(2):421-9. PubMed ID: 17077163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of anterior chamber-associated immune deviation (ACAID) by allogeneic intraocular tumors does not require splenic metastases.
    Niederkorn JY; Streilein JW
    J Immunol; 1982 Jun; 128(6):2470-4. PubMed ID: 6804562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.